Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-aminolevulinic acid plus conventional radiotherapy for quality of life in glioblastoma
IRCT20140810018745N12Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of 5-aminolevulinic acid in glioblastoma (GBM) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Quality of life. Started Aug 2019; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on IRCT20140810018745N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140810018745N12.